Target Audience:

Diabetes specialists, endocrinologists, primary care physicians, nurse practitioners, certified diabetes educators, physician assistants, and other clinicians who diagnose, manage, and treat patients with type 2 diabetes.

Program Overview:

This activity is an enduring material and consists of online, interactive case studies focused on managing type 2 diabetes. Successful completion is achieved by reading the material, reflecting on its implications in your practice, and completing the assessment component. The estimated time to complete this activity is 1.5 hours.

Statement of Need:

Glucagon-like peptide 1 (GLP-1) receptor agonists (RAs) have the distinction of lowering blood glucose by multiple mechanisms (suppressing glucose-dependent glucagon secretion, stimulating glucose-dependent insulin secretion, and slowing gastric emptying, leading to increased satiety and reduced food intake) and improving other aspects of type 2 diabetes (eg, weight, blood pressure, and lipid parameters). Because GLP-1 RAs are effective in addressing both postprandial glucose and fasting plasma glucose (FPG) requirements, these agents may be introduced early to prevent or delay the progression of type 2 diabetes. Long-acting GLP-1 RAs offer the additional therapeutic advantages of greater FPG and glucagon reductions, larger glycosylated hemoglobin reductions, and lower incidences of gastrointestinal adverse effects by achieving constant and higher plasma drug concentrations. Appropriate patient selection should be based on individual glucose requirements, medical history (eg, overweight/obesity and history of pancreatitis or thyroid cancer), and potential for adherence to antidiabetes medication regimens.


This activity has been planned and implemented in accordance with the Essential Areas and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint sponsorship of Dannemiller and CogniMed Inc. Dannemiller is accredited by the ACCME to provide continuing medical education for physicians.

There is no charge for this activity. CME credit is offered upon successful completion of the Posttest with a minimum score of 70% and submission of the Evaluation after the activity to Dannemiller. A link to the evaluation form is provided upon completion of the activity. If you have any questions about your certificate, please e-mail

Content Review Statement:

To resolve identified/potential conflicts of interest, the educational content was fully reviewed by a physician member of the Dannemiller Clinical Content Review Committee who have no financial relationships with commercial interests. The resulting certified activity was found to provide educational content that is current, evidence based and commercially balanced.

Credit Designation:

Dannemiller designates this enduring material for a maximum of 1.5 AMA PRA Category 1 Credit(s)TM. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Faculty Listing:

Anne L. Peters, MD, FACP, CDE
Director of Clinical Diabetes Programs
Professor of Clinical Medicine
Keck School of Medicine
University of Southern California
Los Angeles, California

Carol H. Wysham, MD
Section Head
Rockwood Clinic Center for Diabetes and Endocrinology
Research Professor of Pharmacotherapy
Washington State University
Spokane, Washington
Associate Clinical Professor of Medicine
University of Washington
Seattle, Washington


  • Describe the prominent role that glucagon-like peptide 1 (GLP-1) receptor agonists (RAs) play in maintaining glucose homeostasis
  • Evaluate the clinical effects of GLP-1 RAs on glucose control and cardiovascular parameters
  • Integrate GLP-1 RA therapy into type 2 diabetes treatment plans early to prevent or delay disease progression
  • Compare and contrast the differentiating properties and effects of GLP-1 RA formulations
  • Select the GLP-1 RA formulation appropriate for a patient based on individual needs

Financial Disclosure:

In accordance with the Accreditation Council for Continuing Medical Education standards, parallel documents from other accrediting bodies, and Dannemiller policy, the following disclosures have been made:

Dannemiller Staff:
John Erikson, MD, PhD, Content Reviewer, has nothing to disclose.

Michelle Montgomery, Director of Continuing Education, has nothing to disclose.

CogniMed Inc. Staff:
Karla Crenshaw-Williams, PhD, Senior Director, Scientific Affairs, and Medical Writer, has nothing to disclose.

Roseann MacLachlan, Senior Program Manager, has nothing to disclose.

Chantel Phipany, Vice President and Director, has nothing to disclose.

Elizabeth Stanton, Editor, has nothing to disclose.

Anne L. Peters, MD, FACP, CDE, is a consultant for Amylin Pharmaceuticals, Inc.; Eli Lilly and Company; and Novo Nordisk and serves on the speakers bureaus of Amylin Pharmaceuticals, Inc.; Eli Lilly and Company; Novo Nordisk; and Takeda Pharmaceuticals North America, Inc.

On behalf of Carol H. Wysham, MD, Rockwood Clinic and/or Washington State University receive research support from Amylin Pharmaceuticals, Inc.; Boehringer Ingelheim; Eli Lilly and Company; Johnson & Johnson; Merck & Co., Inc.; Novo Nordisk; and Sanofi-Aventis. Dr Wysham is a consultant for and serves on the speakers bureaus of Amylin Pharmaceuticals, Inc.; Boehringer Ingelheim; Eli Lilly and Company; and Johnson & Johnson and also serves on the speakers bureaus of Merck & Co., Inc.; Novo Nordisk; and Sanofi-Aventis.

Off-label statement:

This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by FDA. The faculty have been asked to disclose this information when presented. The opinions expressed in the educational activity are those of the faculty. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings. Further, attendees/participants should appraise the information presented critically and are encouraged to consult appropriate resources for any product or device mentioned in this program.


The content and views presented in this educational activity are those of the authors and do not necessarily reflect those of Dannemiller, Amylin Pharmaceuticals, Inc., or CogniMed Inc. This material is prepared based upon a review of multiple sources of information, but it is not exhaustive of the subject matter. Therefore, healthcare professionals and other individuals should review and consider other publications and materials on the subject matter before relying solely upon the information contained within this educational activity.

This piece was written by a medical writer and reviewed by faculty members. Faculty have final editorial control over the piece.